Literature DB >> 19040627

Treatment of vertebral artery origin stenosis with anti-proliferative drug-eluting stents.

Randall C Edgell1, Dileep R Yavagal, Doniel Drazin, Raul Olivera, Alan S Boulos.   

Abstract

BACKGROUND: Vertebral artery origin stenosis is a known cause of stroke that is treatable with angioplasty and stenting. Previous studies have demonstrated that this technique is safe but is limited by high rates of in-stent stenosis. Anti-proliferative drug-eluting stents are an alternative for reducing in-stent stenosis at the vertebral artery origin.
METHODS: This retrospective study included five consecutive patients treated with anti-proliferative drug-eluting stents. The patients' demographics, indications for treatment, procedural technique, and clinical and radiographic follow-up are presented along with a review of the literature.
RESULTS: No peri-procedural complications occurred. One patient had a transient ischemic attack (TIA) during the follow-up period. No patients had hemodynamically significant (>50%) in-stent stenosis at follow-up. Among the 287 cases reported in the literature, there were two strokes (.7%), four TIAs (1.4%), and no procedurally related deaths. Among patients undergoing angiographic follow-up, 26% were found to have >50% in-stent stenosis.
CONCLUSIONS: Anti-proliferative drug-eluting stents hold promise for reducing in-stent stenosis at the vertebral artery origin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040627     DOI: 10.1111/j.1552-6569.2008.00330.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  2 in total

1.  Endovascular treatment of extracranial vertebral artery stenosis.

Authors:  Burak Kocak; Bora Korkmazer; Civan Islak; Naci Kocer; Osman Kizilkilic
Journal:  World J Radiol       Date:  2012-09-28

2.  Treatment of stenoses of vertebral artery origin using short drug-eluting coronary stents: improved follow-up results.

Authors:  Z Vajda; E Miloslavski; T Güthe; S Fischer; G Albes; A Heuschmid; H Henkes
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 3.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.